Picard Medical, Inc. Annual Report: A Summary for Investors

I’ve put together this guide to help you understand how Picard Medical, Inc. (PMI) performed this year. My goal is to explain their complex financial filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Picard Medical creates life-sustaining, implantable heart devices through its subsidiary, SynCardia Systems. Their main product is the SynCardia temporary Total Artificial Heart (TAH). It is the only FDA-approved device used to keep patients alive while they wait for a heart transplant. They sell these specialized pumps and surgical services to about 100 heart transplant centers in the U.S. and abroad.

2. The Big Picture

The company is currently in a "survival and stabilization" phase. For the year ending December 31, 2024, PMI brought in $48.2 million in revenue, a slight drop from the previous year.

Crucially, their auditors issued a "going concern" warning. This means there is significant doubt about the company’s ability to pay its debts and fund operations through 2026. With less than $5 million in cash, they will likely need to borrow more money or sell more shares to stay afloat.

3. Major Wins and Challenges

• The Stock Split: On July 14, 2025, the company performed a 1-for-20 reverse stock split. This helped them meet Nasdaq’s $1.00 minimum price requirement and avoid being delisted.
• Customer Concentration: Their top five customers provide 35% of their total revenue. If they lose even one major hospital contract, their revenue could drop significantly.
• Manufacturing Hurdles: Their products are complex and built by hand in clean rooms. They rely on specific materials and a single factory in Tucson, Arizona. Any supply chain issue or factory shutdown would immediately stop their ability to make money.

4. Financial Health

The company relies heavily on high-interest debt. They carry over $110 million in total liabilities, with some interest rates exceeding 12%. Because they track some debt based on their stock price, their balance sheet changes wildly whenever their stock price moves. To pay off debt, they often issue more shares. This dilutes your ownership, as the total number of shares has grown by over 40% in the last two years.

5. Key Risks

• Cash Flow: The company spends money faster than it earns it. They depend on outside funding that may not be available.
• Regulatory Issues: They must follow strict FDA rules. A recall or a warning letter from the FDA could force them to stop all sales. They also face constant legal risks from potential device malfunctions.
• Cybersecurity: Their "Freedom Driver" system is computer-controlled. A hack could compromise patient data or interfere with the device, leading to massive fines.
• Patent Expiration: Much of their technology is no longer protected by patents. This makes it easier for cheaper competitors to enter the market.

Bottom Line: This is a high-risk investment. The company struggles with heavy debt, a small customer base, and warnings about its future. Treat this as a speculative play that depends entirely on the company finding new cash or drastically improving its operations. Before investing, consider whether you are comfortable with the possibility of share dilution and the company's current reliance on external financing to maintain its daily operations.